BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Elvitegravir: Phase III amended

Gilead amended the ongoing, double-blind Phase III Study GS-US-183-0145 trial of elvitegravir to extend the study period to 96 weeks from 48 based on FDA's recommendation. The trial is comparing once-daily...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >